NCT01419327View on ClinicalTrials.gov

Fosrenol Post-marketing Surveillance for Hemodialysis in Japan

CompletedOBSERVATIONAL
Enrollment

3,267

Participants

Timeline

Start Date

March 23, 2009

Primary Completion Date

January 30, 2019

Study Completion Date

May 28, 2019

Conditions
Hyperphosphatemia
Interventions
DRUG

Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet

Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01419327 - Fosrenol Post-marketing Surveillance for Hemodialysis in Japan | Biotech Hunter | Biotech Hunter